LHRH Agonist

Phase 3Small molecule

Roche

LHRH Agonist is one of 77 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

Prostate CancerActive, not recruiting

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerActive, not recruiting

ProstatectomyActive, not recruiting

Breast CancerPhase 3

Recruiting

Prostate CancerPhase 3

Active, not recruiting

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerPhase 3

Active, not recruiting

ProstatectomyPhase 2

Active, not recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

LHRH Agonist

Roche

Phase 3

7 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Prostate Cancer

NCT05498272

Q1 2027

Phase 2Active, not recruiting

Breast Cancer

NCT06001762

Q2 2027

Phase 3Active, not recruiting

Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

NCT05306340

Q3 2027

Phase 3Active, not recruiting

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

NCT04546009

Phase 1Active, not recruiting

Breast Cancer

NCT03332797

Phase 2Active, not recruiting

Locally Advanced or Metastatic Breast Cancer

NCT04576455

Clinical

Trials by Indication[1]

Prostate Cancer10 trials

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00430183·788 enrolled

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00288080·612 enrolled

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00528866·80 enrolled

Show 7 more trials

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006359·63 enrolled

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.

Completed· Ferring logo

Ferring··NCT02234089·461 enrolled

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00005044·1,579 enrolled

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Active, not recruiting· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00567580·1,792 enrolled

Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists

Completed·RRabin Medical Center·Phase 4·NCT02475057·80 enrolled

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Completed·AAragon Pharmaceuticals, Inc.·Phase 2·NCT01790126·90 enrolled

A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune)

Active, not recruiting·RRana McKay, MD·Phase 2·NCT05498272·32 enrolled

Breast Cancer7 trials

FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer

Active, not recruiting·FFondazione Sandro Pitigliani·Phase 2·NCT03944434·116 enrolled

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Recruiting·FFudan University·Phase 3·NCT05891093·766 enrolled

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Active, not recruiting·UUniversity of Chicago·Phase 2·NCT03879577·53 enrolled

Show 4 more trials

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Terminated· Roche logo

Roche·Phase 1/2·NCT01823835·152 enrolled

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

Withdrawn·UUniversity of Chicago·Phase 2·NCT03058939

A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 1·NCT03332797·181 enrolled

The TRADE Study: A Phase 2 Trial to Assess the ToleRability of Abemaciclib Dose Escalation in Patients With Early-Stage HR-positive and HER2-negative Breast Cancer

Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT06001762·90 enrolled

Prostatectomy2 trials

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01674270·35 enrolled

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00329043·64 enrolled

Locally Advanced or Metastatic Breast Cancer2 trials

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05296798·922 enrolled

A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 2·NCT04576455·303 enrolled

Prostate1 trial

Prostate Boost Irradiation With Stereotactic Body RT (SBRT)

Unknown status·JJuravinski Cancer Center·Phase 2·NCT03380806·100 enrolled

4 more indications

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer1 trial

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05306340·373 enrolled

Early Breast Cancer1 trial

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04961996·4,170 enrolled

Advanced Breast Cancer1 trial

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Active, not recruiting· Roche logo

Roche·Phase 3·NCT06065748·1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer1 trial

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04546009·992 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for LHRH Agonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LHRH Agonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LHRH Agonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

LHRH Agonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Prostate Cancer10 trials

Breast Cancer7 trials

Prostatectomy2 trials

Locally Advanced or Metastatic Breast Cancer2 trials

Prostate1 trial

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer1 trial

Early Breast Cancer1 trial

Advanced Breast Cancer1 trial

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News